Startseite

Kongressberichte & Archiv

Archiv 2017

ESMO 19th World Congress on Gastrointestinal Cancer

Cancer of the Pancreas

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

Symposiumsbericht

TEXT

Welcome and introduction

Michel Ducreux, MD, PhD

SLIDES

Case 1—Metastatic pancreatic adenocarcinoma: What therapy should I select first?

Marc Peeters, MD, PhD

SLIDES

Case 2—Optimal management of progressive metastatic pancreatic adenocarcinoma: Second-line therapy and beyond

Gerald Prager, MD

SLIDES

Importance of nutrition in pancreatic cancer care

Federico Bozzetti, MD

SLIDES

Future perspectives and prIME Points™

Michel Ducreux, MD, PhD

SLIDES

News

First-line NIVO + CT vs CT alone for advanced gastric, gastro-oesophageal junction, & oesophageal adenocarcinoma (CheckMate 649): a new standard

07-07-2021 12:45
Weiterlesen ...
Blood test for early detection of cancer: final study results support screening use. Test can detect over 50 types of cancer, often before symptoms show

24-06-2021 23:01
Weiterlesen ...
Swissmedic Approves TEPMETKO® a Once-Daily Targeted Therapy for NSCLC with a METex14 Skipping Mutation1

23-06-2021 11:32
Weiterlesen ...
Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM

21-06-2021 08:58
Weiterlesen ...
Lehrvideo zur Entfernung von Bauchspeicheldrüsentumoren mittels Robotik

16-04-2021 08:42
Weiterlesen ...
New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

03-04-2021 08:40
Weiterlesen ...
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58
Go to the ELCC/ESMO 2021 PRESS RELEASE
SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15
Go to the ELCC/ESMO 2021 PRESS RELEASE
ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47
ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

News

First-line NIVO + CT vs CT alone for advanced gastric, gastro-oesophageal junction, & oesophageal adenocarcinoma (CheckMate 649): a new standard

Blood test for early detection of cancer: final study results support screening use. Test can detect over 50 types of cancer, often before symptoms show

Swissmedic Approves TEPMETKO® a Once-Daily Targeted Therapy for NSCLC with a METex14 Skipping Mutation1

Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM

Lehrvideo zur Entfernung von Bauchspeicheldrüsentumoren mittels Robotik

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

Newsletter